rawfin.tv
AbbVie Secures FDA Approval for Parkinson's Drug Juvmo
Top Storiesstocks🟠 Score 8AI Generated

AbbVie Secures FDA Approval for Parkinson's Drug Juvmo

By rawfin.tv Markets Desk||Updated |1 min read|AI-assisted · Methodology

AbbVie (ABBV) has received FDA approval for Juvmo (tavapadon), a new once-daily selective dopamine agonist for adult Parkinson's disease. This approval marks a significant milestone for AbbVie, expanding its neuroscience portfolio and potential market share.

AbbViePharmaceuticalsFDA ApprovalParkinson's DiseaseBiotech

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks